Vimarsana
Biggest News Aggregation in the World

Jeff Yordon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Yordon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Yordon Today - Breaking & Trending Today

Avenacy intros generic Alkeran - Vimarsana News

Avenacy intros generic Alkeran

Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market - Vimarsana News

Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Jan 16, 2024--

Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript - Vimarsana News

Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript

ATNX earnings call for the period ending June 30, 2021.

Source: fool.com
Athenex Plant Nearly Complete | News, Sports, Jobs - Vimarsana News

Athenex Plant Nearly Complete | News, Sports, Jobs

JOHNSON LAU Dunkirk’s new Athenex facility is nearing completion as company officials continue pushing for federal approval for its new breast cancer treatment. Athenex has yet to meet with the federal government to address a FDA complete response letter that slowed approval of the company’s new breast cancer treatment. The FDA’s decision in February dealt a hit to Athenex’ stock prices as well as to the company’s bottom line. Still, company officials are moving full steam ahead with Athenex’ Dunkirk facility, according to Jeff Yordon, Athenex chief operating officer, who spoke ...

Athenex plant 'nearly complete' | News, Sports, Jobs - Vimarsana News

Athenex plant 'nearly complete' | News, Sports, Jobs

jwhittaker@post-journal.com Johnson Lau, Athenex chief executive officer, said a meeting with the FDA could happen later this month. Dunkirk’s new Athenex facility is nearing completion as company officials continue pushing for federal approval for its new breast cancer treatment. Athenex has yet to meet with the federal government to address a FDA complete response letter that slowed approval of the company’s new breast cancer treatment. The FDA’s decision in February dealt a hit to Athenex’ stock prices as well as to the company’s bottom line. Still, company officials are moving...